Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-23T16:48:04.846Z Has data issue: false hasContentIssue false

13 - Alzheimer’s Disease Drug Development in Pharmaceutical Companies

from Section 3 - Alzheimer’s Disease Clinical Trials

Published online by Cambridge University Press:  03 March 2022

By
Eric Siemers ,
Robert A. Dean ,
James E. Senetar ,
Janice M. Hitchcock  and
Russell L. Barton
Edited by
Jeffrey Cummings ,
Jefferson Kinney  and
Howard Fillit
Jeffrey Cummings
Affiliation:
University of Nevada, Las Vegas
Jefferson Kinney
Affiliation:
University of Nevada, Las Vegas
Howard Fillit
Affiliation:
Alzheimer’s Drug Discovery Foundation
Get access

Summary

Drug development is a long and arduous process that requires many researchers at different types of institutions. These include researchers in university settings, researchers in government settings, researchers in non-profit organizations and researchers in the pharmaceutical industry. The pharmaceutical industry itself is heterogeneous, ranging from tiny biotech companies to large multi-national organizations. This chapte emphasizes drug development efforts by the pharmaceutical industry but will also make note of the many collaborations between pharma and researchers at other types of institutions.

Keywords

drug developmentpharmaceutical industrybiotechuniversitymulti-national organizationsgovernmentnon-profit
Type
Chapter
Information
Alzheimer's Disease Drug Development
Research and Development Ecosystem
 , pp. 162 - 169
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Siemers, E. Drug development in AD: point of view from the industry. J Prev Alzheimers Dis 2015; 2: 216–18.Google Scholar
Cummings, J, Ritter, A, Zhong, K. Clinical trials for disease-modifying therapies in Alzheimer’s disease: a primer, lessons learned, and a blueprint for the future. J Alzheimers Dis 2018; 64: S3–22.CrossRefGoogle Scholar
Rinaldi, A. Setbacks and promises for drugs against Alzheimer’s disease: as pharmaceutical companies are retreating from drug development for Alzheimer’s, new approaches are being tested in academia and biotech companies. EMBO Rep 2018; 19: e46714.CrossRefGoogle ScholarPubMed
Biogen. Biogen plans regulatory filing for aducanumab in Alzheimer’s disease based on new analysis of larger dataset from Phase 3 studies. Investor Relations 2019; Oct. 22. Available at: https://investors.biogen.com/news-releases/news-release-details/biogen-plans-regulatory-filing-aducanumab-alzheimers-disease (accessed January 2021).Google Scholar
Food and Drug Administration. FDA’s decision to approve new treatment for Alzheimer’s disease. Available at: www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease (accessed June 2021).Google Scholar
Food and Drug Administration. Early Alzheimer’s Disease: Developing Drugs for Treatment Guidance for Industry. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER); 2018.Google Scholar
European Medicines Agency. Clinical investigation of medicines for the treatment of Alzheimer’s disease: CPMP/EWP/553/1995. Available at: www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicines-treatment-alzheimers-disease-revision-2_en.pdf (accessed January 2021).Google Scholar
Pharmaceuticals and Medical Devices Agency (PMDA). Project to promote the development of innovative pharmaceuticals, medical devices, and regenerative medical products (Ministry of Health, Labour, and Welfare) regulatory science research for the establishment of criteria for clinical evaluation of drugs for Alzheimer’s disease. Available at: www.pmda.go.jp/files/000221585.pdf (accessed January 2021).Google Scholar
Morant, AV, Vestergaard, HT, Lassen, AB, Navikas, V. US, EU, and Japanese regulatory guidelines for development of drugs for treatment of Alzheimer’s disease: implications for global drug development. Clin Transl Sci 2020; 13: 652–64.Google Scholar
Food and Drug Administration. Expedited programs for serious conditions: drugs and biologics, May 2014. Available at: www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics (accessed June 2021).Google Scholar
Food and Drug Administration. Summary memorandum. Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2021/Aducanumab_BLA761178_Dunn_2021_06_07.pdf (accessed June 2021).Google Scholar
Centers for Medicare and Medicaid Services. Decision memo for beta amyloid positron emission tomography in dementia and neurodegenerative disease (CAG-00431N). Available at: www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=265 (accessed January 2021).Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×